EQ stock forecast
Our latest prediction for Equillium, Inc.'s stock price was made on the Feb. 18, 2020 when the stock price was at 5.06$.
In the short term (2weeks), EQ's stock price should underperform the market by -2.28%. During that period the price should oscillate between -10.43% and +13.96%.
In the medium term (3months), EQ's stock price should underperform the market by -2.91%. During that period the price should oscillate between -39.63% and +35.14%.Get email alerts
About Equillium, Inc.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.33$ per share.
The book value per share is 3.42$
Three months stock forecastFeb. 18, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|